The Zhitong Finance App learned that Rebang Pharmaceutical-B (09637) bottomed out and rebounded strongly today. The highest increase of nearly 4% was HK$19.41, with a turnover of HK$17.887 million, or 13.53%.

According to the news, the Hong Kong stock innovative drug sector collectively strengthened today. The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose 3.9% at the beginning of the market, Conoa-B (02162) rose more than 12%, BeiGene (06160) rose more than 5%, and Cinda Biotech (01801) and Kangfang Biotech (09926) rose more than 4%; Driven by Kangfang Biotech's evosimab head-to-head phase III research data, driven by the acceleration of innovative drug BD outbound and AI pharmaceutical-themed resonance, the overall market rebounded according to the common sector. Revise Rebang Pharmaceutical-B mapping pricing. At the individual stock level, Peking University First Hospital recently revealed that the new-generation IgA protease AP308/pku308, jointly developed by its Nephrology Department Lu Jicheng/Zhang Hong team and Libang Pharmaceutical, has been approved by the US FDA for a new drug clinical trial (IND) to treat IgA nephropathy (IgA) and is about to enter the first human clinical research stage; AP308 is a first-in-class (first-in-class) drug in the field of IgA nephropathy, which directly cuts and removes pathogenic IgA and IgA complex immune compounds already deposited in glomeruli through IgA protease . Furthermore, on September 28, Shanghai Libang Pharmaceutical Technology Co., Ltd.'s application for “AP308 for injection” was accepted by the Drug Review Center of the State Drug Administration. The acceptance number is CXSL2601066.

It is worth noting that Rebon Pharmaceuticals is a biomedical company focusing on kidney disease and related chronic diseases. It is the first innovative pharmaceutical company on the Hong Kong stock market with a pure nephropathy circuit 18A. The product portfolio covers different stages and complications of chronic kidney disease (CKD), including 7 candidate products under development and 1 commercialized product, Mexilla®. According to the company's interim results, revenue for the first half of 2026 was 104.2 million yuan, up 761.2% year on year, including sales revenue of 24.8 million yuan, up about 105% year on year, and net loss during the period narrowed by 22.5% year on year; in terms of pipelines, the AP301 capsule new drug marketing application in August was accepted by the State Drug Administration, and the AP306 global phase IIb multi-regional clinical trial was completed in July.